Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt
- 1 May 2009
- journal article
- research article
- Published by Elsevier BV in Kidney International
- Vol. 75 (9), 936-944
- https://doi.org/10.1038/ki.2009.9
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- Fadrozole Reverses Cardiac Fibrosis in Spontaneously Hypertensive Heart Failure Rats: Discordant Enantioselectivity Versus Reduction of Plasma AldosteroneEndocrinology, 2007
- Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiencyKidney International, 2007
- Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injuryKidney International, 2006
- Combined Treatment With Valsartan and Spironolactone Prevents Cardiovascular Remodeling in Renovascular Hypertensive RatsInternational Heart Journal, 2006
- Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophyCanadian Journal of Physiology and Pharmacology, 2005
- Nongenomic Effects of Aldosterone in the Human HeartHypertension, 2005
- Aldosterone Synthase Inhibitor Ameliorates Angiotensin II–Induced Organ DamageCirculation, 2005
- Angiotensin II and Aldosterone Regulate Gene Transcription Via Functional Mineralocortocoid Receptors in Human Coronary Artery Smooth Muscle CellsCirculation Research, 2005
- Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal diseaseAmerican Journal of Hypertension, 2005
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999